Abstract Library

#3041 Resource Use in Patients with Carcinoid Syndrome: A Retrospective Analysis Using the French Health Insurance National (SNDS) Database

Introduction: About 20% of patients (pts) with neuroendocrine tumors (NET) suffer from carcinoid syndrome (CS), mainly from ileum and lung NET. Pts with CS experience symptoms such as diarrhea, flushes and cardiac complications. The diarrhea occurs in almost all pts with CS and can be truly debilitating. Therefore, on top of the tumor, the burden of the symptoms further impairs quality of life and is associated with additional costs related to symptom management and pts follow-up.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Walter T

Authors: Walter T, Lapeyre Mestre M, Gueguen D, Bouille C, Laborey M,

Keywords: Carcinoid syndrome, resources, health economics,

#2846 Whole Genome DNA Methylation Profiling Identifies Neuroendocrine Tumor Origin

Introduction: Determining the origin of a neuroendocrine tumor (NET) of unknown primary can be challenging. Liver metastases can originate from any organ in the body, while pulmonary NETs can be metastases but also primary tumors. This especially holds true for Multiple Endocrine Neoplasia Type 1 patients, who often have multiple primary pancreatic and intestinal NETs. It is important to know the origin of the primary tumor since resection or ablation is crucial in case of treatment with curative intent. Furthermore, the site of origin determines prognosis, treatment options and eligibility for clinical trials.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Hackeng W, Geisenberger C, de Leng W, Morsink F, Vriens M,

Keywords: Methylation profiling, Neuroendocrine tumor, Machine Learning, Unknown Primary,

#2067 Recognition of Primary Neuroendocrine Tumors - A Challenge

Introduction: Neuro endocrine tumors of liver are rare.Most of the neuroendocrine tumors of the liver arise from gastrointestinal tract, especially from appendix.ileum and pancreas.Primary hepatic neuro endocrine tumors is a rare clinical entity, requiring strict exclusion of possible extra-hepatic primary sites for its diagnosis.Most challenging in diagnosis is diversity in presentation of primary symptoms.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Athar A,

Keywords: primary symptoms, optimal management, better prognosis,

#1662 Two Separate Modified ENETS Staging Classifications Are Needed for Duodenal and Jejunoileal Neuroendocrine Neoplasms

Introduction: Previous studies showed duodenal neuroendocrine neoplasms (d-NEN) and jejunoileal NEN (j-NEN) harboring different features. However, the staging classifications of d-NEN and j-NEN proposed by ENETS are identical.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Chen L

Authors: Chen L, Zhang Y, Chen M, Chen J,

Keywords: stage, duodenum, jejunoileum, neuroendocrine neoplasms,

#1495 Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety from a RADIANT-4 Subgroup Analysis

Introduction: Everolimus (EVE) demonstrated progression-free survival (PFS) benefit of 7.1 months compared to placebo in the phase 3 RADIANT-4 study in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Singh S

Authors: Singh S, Carnaghi C, Buzzoni R, Raderer M, Lahner H,

Keywords: Everolimus, progression-free survival, gastrointestinal NET,